Expression of E‐cadherin in primary prostate cancer: correlation with clinical features

Abstract

Objective To correlate the immunohistochemically of decreased E-cadherin expression for the long-term or recurrence-free survival of patients, using a threshold detected loss of E-cadherin expression with patient age, clinical and biological variables, and to investigate value of 40% for the relative amount of positively stained tumour cells, or for any other threshold value the prognostic value of these variables for the relapsefree and overall survival of patients with diCerent calculated (25%, 60% or 75%). However, comparing a follow-up of 16 months in patients with <40% stages of newly diagnosed prostate cancer. Patients and methods Sixty-seven patients (median age positivity and 46 months in patients with Á40% positivity, those patients retaining E-cadherin 63 years, range 48-78) undergoing radical prostatectomy for the treatment of primary prostate cancer expression had a significantly longer recurrence-free interval after radical prostatectomy (P<0.01). were assessed to determine whether age, tumour stage, histological grading, serum levels of prostate specific Conclusion The value of E-cadherin expression as an additional independent prognostic variable for patients antigen and prostatic acid phosphatase, regional lymph node status and E-cadherin expression were with primary prostate cancer is questionable. Keywords E-cadherin, expression, prostate cancer, radprognostic factors for relapse-free and overall survival. Results With a median (range) follow-up of 54 (3-193) ical prostatectomy, clinical prognosis months, there was no independent prognostic value brane 120 kDa glycoprotein belonging to the group of

Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors

“…For example, the clinical value of a prognostic biomarker would be assured by its ability to predict biochemical recurrence and the potential need for adjuvant therapy or, indeed, by its ability to discriminate tumours of low malignant potential before surgery. This study did not show any clinically useful prognostic value associated with in-E-cadherin fails to predict biochemical relapse in patients treated for prostate cancer [20,12,41] (Table 8).…”

“…6 13-44 Sig. P = 0.003 N/P Brewster et al [20] 76 pT1-4 4-10 0.9-37 22-37 NS N/P Kuczyk et al [12] 67 pT1-4 2-10 N/A N/A NS NS Rhodes et al [41] 259 pT2-4 2-10 0.5-43 N/A NS N/P Abbreviations: Sig, significant; NS, non-significant, N/A, not available, N/P, not performed; PSA, prostate-specific antigen.…”

“…Thus, an adverse prognosis may be observed with a loss of E-cadherin expression at radical prostatectomy, although aberrant expression is also correlated with high tumour grade and more advanced pathological stage [9][10][11]. Other studies have questioned the independent prognostic value of E-cadherin expression [12,13], with the possibility of transient downregulation in localized disease that precedes development of the metastatic phenotype [14].…”

E-cadherin gene mutations are rare in adenocarcinomas of the oesophagus

“…E-cadherin-negative epithelial cells grow invasive with a mesenchymal phenotype. After transfection with E-cadherin cDNA, epithelial structure is restored (Frixen et al, 1991;Vleminckx et al, 1991).Consistent with this observation is a reduced or absent E-cadherin expression in various epithelial cancers showing invasive growth (Gabbert et al, 1996;Kuczyk et al, 1998;Sulzer et al, 1998). Decreased expression of E-cadherin in Barrett's oesophagus, adenocarcinomas of the oesophagus and gastrooesophageal junction was found to be related with progression of Barrett's oesophagus to adenocarcinoma, tumour stage and lymph node metastasis (Bongiorno et al, 1995;Bailey et al, 1998).…”

N-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin

“…We next scored the immunoreactivity of NDRG1/Cap43 and E-cadherin membranous expression by estimating the percentage of strongly positive tumor cells. Membranous expression has been used to evaluate E-cadherin expression in prostate cancer, and decreased membranous expression has been defined as aberrant expression [21,23,[27][28][29]. The authors of some studies reported that the positive cytoplasmic expression of E-cadherin was also included in the aberrant expression [21,27].…”